Efficacy and Safety of ANB032 in the Treatment of Subjects with Atopic Dermatitis

Prior treatment

• Not able to tolerate SC drug administration
• Tanning booth use or extended sun exposure that could affect disease severity or interfere with disease assessments within 4 weeks before Randomization
• Received or plans to initiate during the study any of the following prescribed medications or therapies: Systemic Janus kinase (JAK) inhibitors at any time prior to Day 1, Immunomodulatory biologic agents received within 12 weeks or 5 half lives (t1/2; whichever is longer) before Day 1, Phototherapy treatment or laser therapy that could affect disease severity or interfere with disease assessments within 4 weeks before Day 1, Systemic therapy for AD, including but not limited to, corticosteroids, methotrexate, cyclosporine, azathioprine, phosphodiesterase type 4 (PDE 4) inhibitors, IFN γ, and mycophenolate mofetil within 4 weeks before Day 1, Use of topical treatments for AD including but not limited to corticosteroids, tacrolimus, pimecrolimus, JAK inhibitors, or PDE-4 inhibitors within 14 days before Day 1, Live or live attenuated vaccines within 12 weeks before Day 1

Other illness

• Any factors that in the Investigator's opinion would predispose the subject to develop an infection
• Known or suspected congenital or acquired immunodeficiency state, or condition that would compromise the subject's immune status

• Male or female aged 18 to 65 years and in good general health
• Moderate or severe atopic dermatitis continuously for at least 6 months prior to randomization
• History of inadequate response to both topical corticosteroids and topical calcineurin inhibitors or for whom topical treatments are otherwise medically inadvisable
• EASI score >=16 at Screening and at Randomization
• vIGA-AD score >=3 at Screening and at Randomization
• AD-involved BSA>=10% at Screening and at Randomization